Essential Tremor - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Essential Tremor - Pipeline Review, H1 2016

Essential Tremor - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Essential Tremor - Pipeline Review, H1 2016
Published May 31, 2016
49 pages — Published May 31, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Essential Tremor - Pipeline Review, H1 2016, provides an overview of the Essential Tremor pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Essential Tremor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Essential Tremor and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Essential Tremor
- The report reviews pipeline therapeutics for Essential Tremor by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Essential Tremor therapeutics and enlists all their major and minor projects
- The report assesses Essential Tremor therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Essential Tremor

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Essential Tremor
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Essential Tremor pipeline depth and focus of Indication therapeutics&

  
Source:
Document ID
GMDHC8154IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Essential Tremor Overview61
Therapeutics Development71
  Pipeline Products for Essential Tremor Overview71
Essential Tremor Therapeutics under Development by Companies81
Essential Tremor Pipeline Products Glance92
  Clinical Stage Products91
  Early Stage Products101
Essential Tremor Products under Development by Companies111
Essential Tremor Companies Involved in Therapeutics Development123
  Merz GmbH &Co. KGaA121
  Neurocrine Biosciences, Inc.131
  Sage Therapeutics, Inc.141
Essential Tremor Therapeutics Assessment159
  Assessment by Monotherapy Products151
  Assessment by Target162
  Assessment by Mechanism of Action182
  Assessment by Route of Administration202
  Assessment by Molecule Type222
Drug Profiles249
  incobotulinumtoxin A - Drug Profile241
    Product Description241
    Mechanism of Action241
    R&D Progress243
  NBI-640756 - Drug Profile271
    Product Description271
    Mechanism of Action271
    R&D Progress271
  SAGE-217 - Drug Profile281
    Product Description281
    Mechanism of Action281
    R&D Progress281
  sepranolone - Drug Profile291
    Product Description291
    Mechanism of Action291
    R&D Progress293
  Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile321
    Product Description321
    Mechanism of Action321
    R&D Progress321
Essential Tremor Recent Pipeline Updates338
Essential Tremor - Dormant Projects411
Essential Tremor Discontinued Products421
Essential Tremor Product Development Milestones435
  Featured News &Press Releases431
    Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting431
    Nov 04, 2015: Neurocrine Biosciences Announces Expansion of its Clinical Pipeline441
    Sep 03, 2015: SAGE Therapeutics Announces Results From Successful Exploratory Trial in Essential Tremor452
    Oct 23, 2014: SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor471
Appendix482
  Methodology481
  Coverage481
  Secondary Research481
  Primary Research481
  Expert Panel Validation481
  Contact Us481
  Disclaimer491

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Essential Tremor - Pipeline Review, H1 2016" May 31, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Essential-Tremor-Pipeline-Review-H1-2016-2088-15905>
  
APA:
Global Markets Direct - Market Research. (2016). Essential Tremor - Pipeline Review, H1 2016 May 31, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Essential-Tremor-Pipeline-Review-H1-2016-2088-15905>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.